Umbilical cord blood cell and granulocyte-colony stimulating factor: combination therapy for traumatic brain injury [0.03%]
脐带血细胞和粒细胞集落刺激因子：创伤性脑损伤的联合治疗
Ike de la Peña,Paul R Sanberg,Sandra Acosta et al.
Ike de la Peña et al.
FGF-2: a critical factor for producing myogenic progenitors and skeletal muscle from pluripotent sources? [0.03%]
FGF-2：从多能干细胞中生成肌源性前体细胞和骨骼肌的关键因素？
Jonathan M Van Dyke,Masatoshi Suzuki
Jonathan M Van Dyke
Carol B Ware
Carol B Ware
Biodegradable elastomers for biomedical applications and regenerative medicine [0.03%]
用于生物医学和再生医学的可降解弹性体
Erhan Bat,Zheng Zhang,Jan Feijen et al.
Erhan Bat et al.
Synthetic biodegradable polymers are of great value for the preparation of implants that are required to reside only temporarily in the body. The use of biodegradable polymers obviates the need for a second surgery to remove the implant, wh...
Fanwei Meng,Michel Modo,Stephen F Badylak
Fanwei Meng
Injury to the CNS typically results in significant morbidity and endogenous repair mechanisms are limited in their ability to restore fully functional CNS tissue. Biologic scaffolds composed of individual purified components have been shown...
Health consumers and stem cell therapy innovation: markets, models and regulation [0.03%]
卫生消费者与干细胞治疗创新：市场、模式和监管政策
Brian Salter,Yinhua Zhou,Saheli Datta
Brian Salter
Global health consumer demand for stem cell therapies is vibrant, but the supply of treatments from the conventional science-based model of innovation is small and unlikely to increase in the near future. At the same time, several models of...
Regulation of cell-based therapeutic products intended for human applications in the EU [0.03%]
欧盟人类细胞治疗产品的监管政策现状及挑战展望——从药品监管的视角
Marko O Närhi,Katrina Nordström
Marko O Närhi
Aims: Recent developments in the field of cell-based therapeutic products (CBTPs) have forced the EU to revise its legislation on therapeutic products by enacting several new legal instruments. In this study, we investiga...